List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
Boehringer Ingelheim announced that the European Commission has granted EU…
27 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU...
The European Commission granted marketing authorisation for Eli Lilly and…
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
Boehringer Ingelheim today announced the U.S. Food and Drug Administration…
4 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.
Results from a Phase II study, published in the American…
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31…
2 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler...
The U.S. Food and Drug Administration has granted Breakthrough Therapy…
30 June 2014 | By Boehringer Ingelheim
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab...
Boehringer Ingelheim and Eli Lilly and Company presented results of…
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved…
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
The European Commission has granted Marketing Authorisation for empagliflozin, a…
23 May 2014 | By Boehringer Ingelheim
The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company...
Boehringer Ingelheim announced new overall survival results from a post-hoc…
15 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
Boehringer Ingelheim announced that the US Food and Drug Administration…
17 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the US Food and Drug Administration and the European Commission have granted volasertib* ‘orphan drug designation' for the treatment of patients with acute myeloid leukaemia...
Boehringer Ingelheim has announced that new findings from ongoing Pradaxa®…
24 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim has announced that new findings from ongoing Pradaxa® research will be presented during the American College of Cardiology's 63rd Annual Scientific Session...
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment…
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was…
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced…
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
